A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

Clinical trial NCT05048797 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05048797
Sponsor: AstraZeneca
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Start date: 2021-10-28
Primary completion: 2026-06-09
Enrollment: 454

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.